{"brief_title": "Study of CEP-701 (Lestaurtinib) in Patients With Acute Myeloid Leukemia (AML)", "brief_summary": "The purpose of the study is to determine whether CEP-701 given in sequence with induction chemotherapy increases the proportion of patients with relapsed acute myeloid leukemia (AML) who achieve a second complete remission (CR).", "detailed_description": "Patients randomly assigned to chemotherapy alone received the second course of induction chemotherapy as soon as clinically indicated; patients randomly assigned to receive chemotherapy plus sequential lestaurtinib had lestaurtinib withheld for 3 days (72 hours) before the start of the second 5-day course of chemotherapy and resumed lestaurtinib treatment 2 days (48 hours) after the final administration of the second course of chemotherapy.", "condition": ["Acute Myeloid Leukemia"], "intervention_type": ["Drug", "Drug", "Drug"], "intervention_name": ["CEP-701", "high-dose cytarabine", "Mitozantrone, Etoposide, Cytarabine (combination Chemotherapy)"], "arm_group_label": ["1", "2", "2", "1"], "other_name": ["lestaurtinib", "HiDAC", "MEC"], "description": ["Chemotherapy", "Chemotherapy"], "criteria": "Inclusion criteria: - cytological confirmation of AML; - relapsed disease following first CR of 1 month(30days)to 24 months(730days). The time from first relapse to study entry (start of first course of induction chemotherapy) must be no longer than 30days; - confirmation of FLT-3 activating mutation positive status after point of initial relapse; - aged 18 years or older; - written informed consent; - ability to understand and comply with study restrictions; - no comorbid conditions that would limit life expectancy to less than 3 months; - ECOG Performance Score of 0, 1,or 2; - women must be neither pregnant nor lactating, and either of non-childbearing potential or using adequate contraception with a negative pregnancy test at study entry Exclusion criteria: - bilirubin > 2x ULN; - ALT/AST > 3x ULN; - serum creatinine > 1.5 mg/dL; - resting ejection fraction of left ventricle l < 45%(applies only to patients scheduled to receive mitoxantrone, etoposide, and cytarabine [MEC]; - untreated or progressive infection; - any physical or psychiatric cdtn that may compromise participation in the study; - known CNS involvement with AML; - any previous treatment with a FLT-3 inhibitor; - requires current treatment for HIV with protease inhibitors; - active GI ulceration or bleeding; - use of an investigational drug that is not expected to be cleared by the start of CEP-701 treatment", "gender": "All", "minimum_age": "18 Years", "maximum_age": "N/A", "healthy_volunteers": "No", "keyword": "AML", "mesh_term": ["Leukemia", "Leukemia, Myeloid", "Leukemia, Myeloid, Acute", "Etoposide", "Mitoxantrone", "Cytarabine"], "id": "NCT00079482"}